ArticleFrontiers in pharmacology2021

Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study.

Li Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.